Alnylam Pharmaceuticals Inc

ALNY

465.890USD

-2.815-0.60%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

10 / 176

Overall Ranking

99 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 32 analysts

Buy

Current Rating

435.613

Target Price

-6.50%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 116.72% year-on-year.

Undervalued

The company’s latest PE is -188.25, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 131.78M shares, decreasing 2.43% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 13.24M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

The company's current financial score is 7.91, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 594.19M, representing a year-over-year increase of 20.20%, while its net profit experienced a year-over-year increase of 12.82%.

Score

Industry at a Glance

Previous score

7.91

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.93

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.44

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.11

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is -183.52, which is -86.81% below the recent high of -24.21 and 39.58% above the recent low of -110.88.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/176

No Data

The company’s current earnings forecast score is 7.88, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for Alnylam Pharmaceuticals Inc is 448.50, with a high of 570.00 and a low of 228.50.

Score

Industry at a Glance

Previous score

7.94

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.57, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 499.33 and the support level at 379.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.19

Change

-0.39

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 100.54%, representing a quarter-over-quarter decrease of 1.11%. The largest institutional shareholder is The Vanguard, holding a total of 13.24M shares, representing 10.10% of shares outstanding, with 3.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

16.75M

+0.90%

Fidelity Management & Research Company LLC

14.62M

+13.00%

The Vanguard Group, Inc.

Star Investors

13.00M

+2.55%

Capital Research Global Investors

7.15M

+2.67%

BlackRock Institutional Trust Company, N.A.

6.73M

-0.33%

Regeneron Pharmaceuticals Inc

4.44M

--

T. Rowe Price Investment Management, Inc.

4.42M

+0.77%

Dodge & Cox

Star Investors

3.35M

-5.32%

State Street Global Advisors (US)

3.37M

-1.64%

T. Rowe Price Associates, Inc.

Star Investors

3.41M

+5.52%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.62, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Alnylam Pharmaceuticals Inc

ALNY

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.